-
1Academic Journal
Authors: S.D. Efremova, V.M. Nikolaev, S.I. Sofronova, E.K. Rumyantsev, E.D. Okhlopkova, N.K. Chirikova, S.A. Fedorova
Source: Yakut Medical Journal. :13-16
Subject Terms: 2. Zero hunger, альфа-фетопротеин (АФП), простатический специфический антиген (ПСА), онкомаркеры, онкомаркер яичников (СА125), раково-эмбриональный антиген (РЭА), курение, 3. Good health
-
2Academic Journal
Authors: V. K. Bozhenko, A. M. Shishkin, A. N. Shkoporov, Y. Yu. Kiseleva, T. M. Kulinich, O. B. Bolshakova, E. A. Kudinova, V. A. Solodkiy, В. К. Боженко, А. М. Шишкин, А. Н. Шкопоров, Я. Ю. Киселева, Т. М. Кулинич, О. Б. Большакова, Е. А. Кудинова, В. А. Солодкий
Contributors: The study was carried out with the support of the Ministry of Education and Science of Russia (project #14.N08.11.0018)., Исследование выполнено при поддержке Минобрнауки России (проект #14.N08.11.0018).
Source: Advances in Molecular Oncology; Том 10, № 1 (2023); 79-86 ; Успехи молекулярной онкологии; Том 10, № 1 (2023); 79-86 ; 2413-3787 ; 2313-805X ; 10.17650/2313-805X-2023-10-1
Subject Terms: раково-эмбриональный антиген, chimeric antigen receptors, CAR-T therapy, electroporation, carcinoembryonic antigen, химерный антигенный рецептор, CAR-T-терапия, электропорация
File Description: application/pdf
Relation: https://umo.abvpress.ru/jour/article/view/514/293; Arabi F., Torabi-Rahvar M., Shariati A. et al. Antigenic targets of CAR T cell therapy. A retrospective view on clinical trials. Exp Cell Res 2018;369(1):1–10. DOI:10.1016/j.yexcr.2018.05.009; Brentjens R.J., Davila M.L., Riviere I. et al. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapyrefractory acute lymphoblastic leukemia. Sci Transl Med 2013;5(177):177ra38. DOI:10.1126/scitranslmed.3005930; Kuehn B.M. The promise and challenges of CAR-T gene therapy. JAMA. 2017;318(22):2167–9. DOI:10.1001/jama.2017.15605; Bjerner J., Lebedin Y., Bellanger L. et al. Protein epitopes in carcinoembryonic antigen. Report of the ISOBM TD8 workshop. Tumour Biol 2002;23(4):249–62. DOI:10.1159/000067255; Шишкин А.М. Разработка метода адоптивной иммунотерапии раково-эмбриональный антиген позитивных опухолей человека: автореф. дис. … канд. мед. наук. М., 2015. 22 с.; Bojenko V.K., Shramova E.I., Shkoporov A.N. et al. Monomolecular chimeric T-cell receptor to a carcinoembryonic antigen. WO2013154458A2, 2013.; Bozhenko V.K., Shramova E.I., Shishkin A.M. et al. Characteristics of new monomolecular chimeric T-cell receptors to carcinoembryonic antigen. Bull Exp Biol Med 2013;156(1): 165–71. DOI:10.1007/s10517-013-2302-2; Skorka K., Ostapinska K., Malesa A. et al. The application of CART cells in haematological malignancies. Arch Immunol Ther Exp (Warsz) 2020;68(6):34. DOI:10.1007/s00005-020-00599-x; Hammarstrom S. The carcinoembryonic antigen (CEA) family: structures, suggested functions and expression in normal and malignant tissues. Semin Cancer Biol 1999;9(2):67–81. DOI:10.1006/scbi.1998.0119; Nap M., Mollgard K., Burtin P. et al. Immunohistochemistry of carcino-embryonic antigen in the embryo, fetus and adult. Tumour Biol 1988;9(2–3):145–53. DOI:10.1159/000217555; Boucher D., Cournoyer D., Stanners C.P. et al. Studies on the control of gene expression of the carcinoembryonic antigen family in human tissue. Cancer Res 1989;49(4):847–52.; Zhang C., Wang Z., Yang Z. et al. Phase I escalating-dose trial of CAR-T therapy targeting CEA(+) metastatic colorectal cancers. Mol Ther 2017;25(5):1248–58. DOI:10.1016/j.ymthe.2017.03.010; Yoon S.H., Lee J.M., Cho H.I. et al. Adoptive immunotherapy using human peripheral blood lymphocytes transferred with RNA encoding Her-2/neu-specific chimeric immune receptor in ovarian cancer xenograft model. Cancer Gene Ther 2009;16(6):489–97. DOI:10.1038/cgt.2008.98; Barrett D.M., Zhao Y., Liu X. et al. Treatment of advanced leukemia in mice with mRNA engineered T cells. Hum Gene Ther 2011;22(12):1575–86. DOI:10.1089/hum.2011.070; Mitchell D.A., Nair S.K. RNA-transfected dendritic cells in cancer immunotherapy. J Clin Invest 2000;106(9):1065–9. DOI:10.1172/JCI11405; Emtage P.C., Lo A.S., Gomes E.M. et al. Second-generation anticarcinoembryonic antigen designer T cells resist activation-induced cell death, proliferate on tumor contact, secrete cytokines, and exhibit superior antitumor activity in vivo: a preclinical evaluation. Clin Cancer Res 2008;14(24):8112–22. DOI:10.1158/1078-0432.CCR-07-4910; Wang X., Riviere I. Clinical manufacturing of CAR T cells: foundation of a promising therapy. Mol Ther Oncolytics 2016;3:16015. DOI:10.1038/mto.2016.15; https://umo.abvpress.ru/jour/article/view/514
-
3Academic Journal
Authors: N. V. Severskaya, A. A. Ilyin, I. V. Chebotareva, N. V. Zhelonkina, P. A. Isaev, V. V. Polkin, S. A. Ivanov, A. D. Kaprin, Н. В. Северская, А. А. Ильин, И. В. Чеботарева, Н. В. Желонкина, П. А. Исаев, В. В. Полькин, С. А. Иванов, А. Д. Каприн
Source: Head and Neck Tumors (HNT); Том 12, № 2 (2022); 79-88 ; Опухоли головы и шеи; Том 12, № 2 (2022); 79-88 ; 2411-4634 ; 2222-1468 ; 10.17650/2222-1468-2022-12-2
Subject Terms: RET, cancer embryonic antigen, medullary thyroid carcinoma, screening, раково-эмбриональный антиген, медуллярный рак щитовидной железы, скрининг
File Description: application/pdf
Relation: https://ogsh.abvpress.ru/jour/article/view/780/534; Wells S.A., Asa S.L., Dralle H. et al. American Thyroid Association Guidelines Task Force on Medullary Thyroid Carcinoma. Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. Thyroid 2015;25(6): 567-610. DOI:10.1089/thy.2014.0335.; Elisei R. Routine serum calcitonin measurement in the evaluation of thyroid nodules. Best Pract Res Clin Endocrinol Metab 2008;22(6):941-53. DOI:10.1016/j.beem.2008.09.008.; Pacini F., Fontanelli M., Fugazzola L. et al. Routine measurement of serum calcitonin in nodular thyroid diseases allows the preoperative diagnosis of unsuspected sporadic medullary thyroid carcinoma. J Clin Endocrinol Metab 1994;78(4): 826-9. DOI:10.1210/jcem.78.4.8157706.; Elisei R., Bottici V., Luchetti F. et al. Impact of routine measurement of serum calcitonin on the diagnosis and outcome of medullary thyroid cancer: experience in 10,864 patients with nodular thyroid disorders. J Clin Endocrinol Metab 2004;89(1):163-8. DOI:10.1210/jc.2003-030550.; Elisei R., Romei C. Calcitonin estimation in patients with nodular goiter and its significance for early detection of MTC: European comments to the guidelines of the American Thyroid Association. Thyroid Res 2013;6(Suppl 1):S2. DOI:10.1186/1756-6614-6-S1-S2.; Karges W., Dralle H., Raue F. et al. German Society for Endocrinology (DGE) - Thyroid Section. Calcitonin measurement to detect medullary thyroid carcinoma in nodular goiter: German evidence-based consensus recommendation. Exp Clin Endocrinol Diabetes 2004;112(1):52-8. DOI:10.1055/s-2004-815727.; Бельцевич Д.Г., Ванушко В.Э., Мельниченко Г.А. и др. Российские клинические рекомендации по диагностике и лечению дифференцированного рака щитовидной железы у взрослых. Проект. Редакция 2016 г. Эндокринная хирургия 2015;9(3):7-14. DOI:10.14341/serg201537-14.; Costante G., Meringolo D., Durante C. et al. Predictive value of serum calcitonin levels for preoperative diagnosis of medullary thyroid carcinoma in a cohort of 5817 consecutive patients with thyroid nodules. J Clin Endocrinol Metab 2007;92(2): 450-5. DOI:10.1210/jc.2006-1590.; Toledo S.P., Lourenjo D.M., Santos M.A. et al. Hypercalcitoninemia is not pathognomonic of medullary thyroid carcinoma. Clinics (Sao Paulo) 2009;64(7):699-706. DOI:10.1590/S1807-59322009000700015.; Nozieres C., Chardon L., Goichot B. et al. Neuroendocrine tumors producing calcitonin: characteristics, prognosis and potential interest of calcitonin monitoring during follow-up. Eur J Endocrinol 2016; 174(3):335-41. DOI:10.1530/EJE-15-0917.; Censi S., Cavedon E., Fernando S.W. et al. Calcitonin measurement and immunoassay interference: a case report and literature review. Clin Chem Lab Med 2016;54(12): 1861-70. DOI:10.1515/cclm-2015-1161.; Giovanella L., Suriano S. Spurious hypercalcitoninemia and heterophilic antibodies in patients with thyroid nodules. Head Neck 2011;33(1):95-7. DOI:10.1002/hed.21405.; Lupoli G.A., Barba L., Liotti A. et al. Falsely elevated thyroglobulin and calcitonin due to rheumatoid factor in non-relapsing thyroid carcinoma: a case report. Medicine (Baltimore) 2019;98(5):e14178. DOI:10.1097/MD.0000000000014178.; Alves T.G., Kasamatsu T.S., Yang J.H. et al. Macrocalcitonin is a novel pitfall in the routine of serum calcitonin immunoassay. J Clin Endocrinol Metab 2016;101(2):653-8. DOI:10.1210/jc.2015-3137.; Loveday C., Josephs K., Chubb D. et al. p.Val804Met, the most frequent pathogenic mutation in RET, confers a very low lifetime risk of medullary thyroid cancer. J Clin Endocrinol Metab 2018;103(11):4275-82. DOI:10.1210/jc.2017-02529.; Mian C., Perrino M., Colombo C. et al. Refining calcium test for the diagnosis of medullary thyroid cancer: cutoffs, procedures, and safety. J Clin Endocrinol Metab 2014;99(5):1656-64. DOI:10.1210/jc.2013-4088.; Niederle M.B., Scheuba C., Gessl A. et al. Calcium-stimulated calcitonin - the “new standard” in the diagnosis of thyroid C-cell disease - clinically relevant gender-specific cut-off levels for an “old test”. Biochem Med (Zagreb) 201815;28(3):030710. DOI:10.11613/BM.2018.030710.; Allelein S., Ehlers M., Morneau C. et al. Measurement of basal serum calcitonin for the diagnosis of medullary thyroid cancer. Horm Metab Res 2018;50(1):23-8. DOI:10.1055/s-0043-122237.; Haugen B.R., Alexander E.K., Bible K.C. et al. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: the American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid 2016;26(1): 1-133. DOI:10.1089/thy.2015.0020.; Colombo C., Verga U., Mian C. et al. Comparison of calcium and pentagastrin tests for the diagnosis and followup of medullary thyroid cancer. J Clin Endocrinol Metab 2012;97(3):905-13. DOI:10.1210/jc.2011-2033.; Trimboli P., Giannelli J., Marques B. et al. Head-to-head comparison of FNA cytology vs. calcitonin measurement in FNA washout fluids (FNA-CT) to diagnose medullary thyroid carcinoma. A systematic review and meta-analysis. Endocrine 2021;75(1):33-9. DOI:10.1007/s12020-021-02892-x.; Trimboli P., Cremonini N., Ceriani L. et al. Calcitonin measurement in aspiration needle washout fluids has higher sensitivity than cytology in detecting medullary thyroid cancer: a retrospective multicentre study. Clin Endocrinol (Oxf) 2014;80(1):135-40. DOI:10.1111/cen.12234.; Diazzi C., Madeo B., Taliani E. et al. The diagnostic value of calcitonin measurement in wash-out fluid from fine-needle aspiration of thyroid nodules in the diagnosis of medullary thyroid cancer. Endocr Pract 2013;19(5):769-79. DOI:10.4158/EP12420.OR.; Kihara M., Hirokawa M., Kudo T. et al. Calcitonin measurement in fine-needle aspirate washout fluid by electrochemiluminescence immunoassay for thyroid tumors. Thyroid Res 2018;11:15. DOI:10.1186/s13044-018-0059-4.; Rosario P.W., Calsolari M.R. Basal serum calcitonin, after calcium stimulation, and in the needle washout of patients with thyroid nodules and mild or moderate basal hypercalcitoninemia. Horm Metab Res 2017;49(2):129-34. DOI:10.1055/s-0042-121895.; Raue F., Frank-Raue K. Calcitonin screening in nodular goiter-upper limits. Dtsch Arztebl Int 2018;115(13):221. DOI:10.3238/arztebl.2018.0221a.; https://ogsh.abvpress.ru/jour/article/view/780
-
4Book
Authors: Lyndin, Mykola Serhiiovych, Romaniuk, Anatolii Mykolaiovych, Sikora, Vladyslav Volodymyrovych
Subject Terms: клеточная адгезия, неопластическая трансформация, neoplastic transformation, раково-эмбриональный антиген, cancer-embryonic antigen, клітинна адгезія, cell adhesion, раково-ембріональний антиген, неопластична трансформація
File Description: application/pdf
-
5
-
6Academic Journal
Authors: M. B. Dolgushin, A. I. Mikhaylov, S. S. Gordeev, М. Б. Долгушин, А. И. Михайлов, С. С. Гордеев
Source: Surgery and Oncology; Том 9, № 2 (2019); 11-15 ; Хирургия и онкология; Том 9, № 2 (2019); 11-15 ; 2949-5857 ; 10.17650/2220-3478-2019-9-2
Subject Terms: совмещенная с компьютерной томографией, сarcinoembryonic antigen, 18F-fluorodeoxyglucose, positron emission tomography combined with computed tomography, раково-эмбриональный антиген, 18F-фтордезоксиглюкоза, позитронно-эмиссионная томография
File Description: application/pdf
Relation: https://www.onco-surgery.info/jour/article/view/286/239; Kitajima K., Murakami K., Yamasaki E. et al. Performance of integrated FDG PET/contrast-enhanced CT in the diagnosis of recurrent colorectal cancer: comparison with integrated FDG PET/non-contrast-enhanced CT and enhanced CT. Eur J Nucl Med Mol Imaging 2009;36(9):1388—96. PMID: 19370346. DOI:10.1007/s00259-009-1081-5.; Hammond K., Margolin D.A. The role of postoperative surveillance in colorectal cancer. Clin Colon Rectal Surg 2007;20(3):249-54. PMID: 20011206. DOI:10.1055/s-2007-984869.; Adam R., Pascal G., Azoulay D. et al. Liver resection for colorectal metastases: the third hepatectomy. Ann Surg 2003;238(6):871—84. PMID: 14631224. DOI:10.1097/01sla.0000098112.04758.4e.; Simmonds P.C., Primrose J.N., Colquitt J.L. et al. Surgical resection of hepatic metas-tases from colorectal cancer: a systematic review of published studies. Br J Cancer 2006;94:982-99. DOI:10.1038/sj.bjc.6603033. PMID: 16538219.; Berger K.L., Nicholson S.A., Dehdashti F., Siegel B.A. FDG PET evaluation of mucinous neoplasms: correlation of FDG uptake with histopathologic features. AJR Am J Roentgenol 2000;174(4):1005—8. PMID: 10749239. DOI:10.2214/ajr.174.4.1741005.; Zhu A., Lee D., Shim H. Metabolic positron emission tomography imaging in cancer detection and therapy response. Semin Oncol 2011;38(1):55—69. PMID: 21362516. DOI:10.1053/j.semi-noncol.2010.11.012.; Cipe G., Ergul N., Hasbahceci M. et al. Routine use of positron-emission tomog-raphy/computed tomography for staging of primary colorectal cancer: does it affect clinical management? World J Surg Oncol 2013;11(1):49. PMID: 23445625. DOI:10.1186/1477-7819-11-49.; Lee J.H., Lee M.R. Positron emission to-mography/computed tomography in the staging of colon cancer. Ann Coloproctol 2014;30(1):23—7. PMID: 24639967. DOI:10.3393/ac.2014.30.1.23.; Orlacchio A., Schillaci O., Fusco N. et al. Role of PET/CT in the detection of liver metastases from colorectal cancer. Radiol Med 2009;114(4):571—85. PMID: 19444590. DOI:10.1007/s11547-009-0393-7.; Travaini L.L., Trifiro G., Ravasi L. et al. Role of [18F]FDG-PET/CT after radiofrequency ablation of liver metastases: preliminary results Eur J Nucl Med Mol Imaging 2008;35(7):1316—22. PMID: 18338164. DOI:10.1007/s00259-008-0748-7.; Benson A.B., Venook A.P., Al-Hawary M.M. et al. NCCN Guidelines Insights: Colon Cancer, version 2.2018. J Natl Compr Canc Netw 2018;16(4):359—69. PMID: 29632055. DOI:10.6004/jnccn.2018.0021.; Benson A.B., Venook A.P., Al-Hawary M.M. et al. Rectal Cancer, version 2.2018, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 2018;16(7):874—901. PMID: 30006429. DOI:10.6004/jnccn.2018.0061.; Steele S.R., Chang G.J., Hendren S. et al. Practice guideline for the surveillance of patients after curative treatment of colon and rectal cancer. Dis Colon Rectum 2015;58(8):713—25. PMID: 26163950. DOI:10.1097/DCR.0000000000000410.; Kuker R.A., Mesoloras G., Gulec S.A. Optimization of FDG-PET/CT imaging protocol for evaluation of patients with primary and metastatic liver disease. Int Semin Surg Oncol 2007;4(1):17. PMID: 17623095. DOI:10.1186/1477-7800-4-17.; De Bruyne S., Van Damme N., Smeets P. et al. Value of DCE-MRI and FDG-PET/ CT in the prediction of response to preoperative chemotherapy with bevacizumab for colorectal liver metastases. Br J Cancer 2012;106(12):1926—33. PMID: 22596235. DOI:10.1038/bjc.2012.184.; Werner M.K., Brechtel K., Beyer T. et al. PET/CT for the assessment and quantification of 90 Y biodistribution after selective internal radiotherapy (SIRT) of liver metastases. Eur J Nucl Med Mol Imaging 2010;37(2):407—8. PMID: 19997914. DOI:10.1007/s00259-009-1317-4.; Bienert M., McCook B., Carr B.I. et al. 90Y microsphere treatment of unresectable liver metastases: changes in 18F-FDG uptake and tumour size on PET/CT. Eur J Nucl Med Mol Imaging 2005;32(7):778—87. PMID: 15772860. DOI:10.1007/s00259-004-1752-1.; Petersen R.K., Hess S., Alavi A. et al. Clinical impact of FDG-PET/CT on colorectal cancer staging and treatment strategy. Am J Nucl Med Mol Imaging 2014;4(5):471—82. PMID: 25143865.; Laurens S.T., Oyen WJ. Impact of Fluoro-deoxyglucose PET/Computed Tomography on the Management of Patients with Colorectal Cancer. PET Clin 2015;10(3):345—60. PMID: 26099671. DOI:10.1016/j.cpet.2015.03.007.; Lu Y.Y., Chen J.H., Chien C.R. et al. Use of FDG-PET or PET/CT to detect recurrent colorectal cancer in patients with elevated CEA: a systematic review and meta-analysis. Int J Colorectal Dis 2013;28(8):1039-47. PMID: 23407908. DOI:10.1007/s00384-013-1659-z.; Flamen P., Hoekstra O.S., Homans F. et al. Unexplained rising carcinoembry-onic antigen (CEA) in the postoperative surveillance of colorectal cancer: the utility of positron emission tomography (PET). Eur J Cancer 2001;37(7):862-9. PMID: 11313174. DOI:10.1016/S0959-8049(01)00049-1.; Khan K., Athauda A., Aitken K. et al. Survival outcomes in asymptomatic patients with normal conventional imaging but raised carcinoembryonic antigen levels in colorectal cancer following positron emission tomography-computed tomography imaging. Oncologist 2016;21(12):1502—08. PMID: 27742904. DOI:10.1634/theoncologist.2016-0222.; Goldstein M.J., Mitchell E.P. Carcinoem-bryonic antigen in the staging and followup of patients with colorectal cancer. Cancer Invest 2005;23(4):338— 51. PMID: 16100946. DOI:10.1081/CNV-58878.; Graham R.A., Wang S., Catalano PJ., Haller D.G. Postsurgical surveillance of colon cancer. Preliminary cost analysis of physician examination, carcinoembry-onic antigen testing, chest X-ray, and colonoscopy. Ann Surg 1998;228(1): 59-63. PMID: 9671067.; Van Cutsem E., Cervantes A., Adam R. et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol 2016;27(8):1386—422. PMID: 27380959. DOI:10.1093/annonc/mdw235.; Fong Y., Fortner J., Sun R.L. et al. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg 1999;230: 309-18. PMID: 10493478.; Simmonds P.C., Primrose J.N., Colquitt J.L. et al. Surgical resection of hepatic metas-tases from colorectal cancer: A systematic review of published studies. Br J Cancer 2006;94:982-99. PMID: 16538219. DOI:10.1038/sj.bjc.6603033.; Huebner R.H., Park K.C., Shepherd J.E. et al. A meta-analysis of the literature for whole-body FDG PET detection of recurrent colorectal cancer. J Nucl Med 2000;41(7):1177—89. PMID: 10914907.; Заривчацкий М.Ф., Мугатаров И.Н., Каменских Е.Д. Хирургическое лечение метастазов колоректального рака в печень. Анналы хирургической гепатологии 2018;23(1):80—7. DOI:10.16931/1995-5464.2018-1-80-87.; Bipat S., van Leeuwen M.S., Comans E.F. et al. Colorectal liver metastases: CT, MR imaging, and PET for diagnosis — metaanalysis. Radiology 2005;237:123-31. PMID: 16100087. DOI:10.1148/ra-diol.2371042060.; Ackland S.P., Jones M., Tu D. et al. A meta-analysis of two randomised trials of early chemotherapy in asymptomatic metastatic colorectal cancer. Br J Cancer 2005;93(11):1236—43. PMID: 16265352. DOI:10.1038/sj.bjc.6602841.; Gade M., Kubik M., Fisker R.V. et al. Diagnostic value of 18F-FDG PET/CT as first choice in the detection of recurrent colorectal cancer due to rising CEA. Cancer Imaging 2015;15:11. PMID: 26263901. DOI:10.1186/s40644-015-0048-y.; Moulton C., Levine M.N., Law C. et al. An Ontario Clinical Oncology Group (OCOG) randomized controlled trial (RCT) assessing FDG PET/CT in resectable liver colorectal adenocarcinoma me-tastases (CAM). J Clin Oncol 2011;29(suppl):abstr. 3520. DOI:10.1200/jco.2011.29.15_suppl.3520.; Maffione A.M., Lopci E., Bluemel C. et al. Diagnostic accuracy and impact on management of 18F-FDG PET and PET/ CT in colorectal liver metastasis: a metaanalysis and systematic review. Eur J Nucl Med Mol Imaging 2015;42(1):152-63. PMID: 25319712. DOI:10.1007/s00259-014-2930-4.
-
7Academic Journal
Authors: D. V. Erygin, N. G. Minaeva, S. A. Ivanov, N. Yu. Dvinskikh, N. Yu. Novikov, B. A. Berdov, A. A. Nevolskikh, A. A. Karpov, Yu. Yu. Mikhalev, I. A. Evtekhov, L. O. Petrov, Д. B. Ерыгин, Н. Г. Минаева, С. А. Иванов, Н. Ю. Двинских, Н. Ю. Новиков, Б. А. Бердов, А. А. Невольских, А. А. Карпов, Ю. Ю. Михалева, И. А. Евтехов, Л. О. Петров
Contributors: A. Tsyb Medical Radiological Research Centre – Branch of the National Medical Radiology Research Centre of the Ministry of Health of the Russian Federation, МРНЦ им. А.Ф. Цыба – филиал ФГБУ «НМИЦ радиологии» Минздрава России
Source: Research and Practical Medicine Journal; Том 5, № 2 (2018); 36-47 ; Research'n Practical Medicine Journal; Том 5, № 2 (2018); 36-47 ; 2410-1893 ; 10.17709/2409-2231-2018-5-2
Subject Terms: лечебный патоморфоз, carcinoerembryonic antigen, chemoradiotherapy, therapeutic pathomorphosis, раково-эмбриональный антиген, химиолучевая терапия
File Description: application/pdf
Relation: https://www.rpmj.ru/rpmj/article/view/265/237; Состояние онкологической помощи населению России в 2016 году. Под ред. А.Д. Каприна, В.В. Старинского, Г.В. Петровой. М.: МНИОИ им. П.А. Герцена – филиал ФГБУ «НМИРЦ» Минздрава России, 2017. 236 с. Доступно по: http://www.oncology.ru/service/statistics/condition/2016.pdf; Cancer Today. M. Ervik, F. Lam, J. Ferlay, L. Mery, I. Soerjomataram, F. Bray. Lyon, France: International Agency for Research on Cancer, 2016. Available from: http://gco.iarc.fr/today https://doi.org/10.1016/s0140-6736(15)00135-x; Campos FG, Calijuri-Hamra MC, Imperiale AR, Kiss DR, Nahas SC, Cecconello I. Locally advanced colorectal cancer: results of surgical treatment and prognostic factors. Arq Gastroenterol. 2011 Oct-Dec;48(4):270-5.; Glimelius B. Which rectal cancers are locally advanced? Oncology (Williston Park). 2012 Aug;26(8):743, 746, 751-2.; Бердов Б.А., Ерыгин Д.В., Невольских А.А. Местно-распространенный и прогностически неблагоприятный рак прямой кишки (определение понятий и методики лечения). Тезисы конференции «Современные аспекты диагностики и лечения колоректального рака», 2015, с. 36.; Ерыгин Д.В., Бердов Б.А., Невольских А.А., Титова Л.Н., Смирнова С.Г. Неоадъювантная химиолучевая терапия местно-распространенного рака прямой кишки. Онкология. Журнал им. П.А. Герцена 2015;4(1):13-20. DOI:10.17116/ onkolog20154113-20; Rodel C, Graeven U, Fietkau R, Hohenberger W, Hothorn T, Arnold D, et al.; German Rectal Cancer Study Group. Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2015 Aug;16(8):979-89. DOI:10.1016/S1470-2045(15)00159-X; Sauer R, Becker H, Hohenberger W, Rodel C, Wittekind C, Fietkau R, et al. Preoperative versus postoperative Chemoradiotherapy for rectal cancer. J Clin Oncol. 2012 Jun 1;30(16):1926-33. DOI:10.1200/JCO.2011.40.1836.; Lim SB, Choi HS, Jeong SY, Kim DY, Jung KH, Hong YS, et al. Optimal surgery time after preoperative chemoradiotherapy for locally advanced rectal cancers. Ann Surg. 2008 Aug;248(2):24351. DOI:10.1097/SLA.0b013e31817fc2a0.; Park IJ, You YN, Agarwal A, Skibber JM, Rodriguez-Bigas MA, Eng C, et al. Neoadjuvant treatment response as an early response indicator for patients with rectal cancer. J Clin Oncol. 2012 May 20;30(15):1770-6. DOI:10.1200/JCO.2011.39.7901; Dayde D, Tanaka I, Jain R, Tai MC, Taguchi A. Predictive and prognostic molecular biomarkers for response to neoadjuvant chemoradiation in rectal cancer. Int J Mol Sci. 2017 Mar 7;18(3). pii: E573. DOI:10.3390/ijms18030573.; Fokas E, Liersch T, Fietkau R, Hohenberger W, Beissbarth T, Hess C, et al. Tumor regression grading after preoperative chemoradiotherapy for locally advanced rectal carcinoma revisited: updated results of the CAO/ARO/AIO-94 trial. J Clin Oncol. 2014 May 20;32(15):1554-62. doi:10.1200/JCO.2013.54.3769; Бердов Б.А., Невольских А.А., Неборак Ю.Т. Латеральный край резекции как фактор прогноза при раке прямой кишки. Сибирский онкологический журнал. 2010;5:5-10.; Lim SH, Chua W, Henderson C, Ng W, Shin JS, Chantrill L, et al. Predictive and prognostic biomarkers for neoadjuvant chemoradiotherapy in locally advanced rectal cancer. Crit Rev Oncol Hematol. 2015 Oct;96(1):67-80. DOI:10.1016/j.critrevonc.2015.05.003.; Duffy MJ, Lamerz R, Haglund C, Nicolini A, Kalousová M, Holubec L, Sturgeon C. Tumor markers in colorectal cancer, gastric cancer and gastrointestinal stromal cancers: European group on tumor markers 2014 guidelines update. Int J Cancer. 2014 Jun 1;134(11):2513-22. DOI:10.1002/ijc.28384.; National Comprehensive Cancer Network (NCCN). Clinical Practice Guidelines in Oncology: Colon Cancer. Version 2.2018. Fort Washington, PA: NCCN; 2018; Becerra AZ, Probst CP, Tejani MA, Aquina CT, González MG, Hensley BJ, et al. Evaluati the prognosti role of elevated preoperati e carcinoembryonic anti en levels in colon cancer pati ts: results from the Nati Cancer Database. Ann Surg Oncol. 2016 May;23(5):1554-61. DOI:10.1245/s10434-015-5014-1.; Colloca G, Venturino A, Vitucci P. Pre-treatment carcinoembryonic antigen and outcome of patients with rectal cancer receiving neo-adjuvant chemo-radiation and surgical resection: a systematic review and meta-analysis. Med Oncol. 2017 Sep 7;34(10):177. DOI:10.1007/s12032-017-1037-8.; Ryan JE, Warrier SK, Lynch AC, Ramsay RG, Phillips WA, Heriot AG. Predicting pathological complete response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer: a systematic review. Colorectal Dis. 2016 Mar;18(3):234-46. DOI:10.1111/codi.13207.; Kim NK, Hur H. New perspectives on predictive biomarkers of tumor response and their clinical application in preoperative chemoradiation therapy for rectal cancer. Yonsei Med J. 2015 Nov;56(6):1461-77. DOI:10.3349/ymj.2015.56.6.1461; Filiz AI, Sucullu I, Kurt Y, Karakas DO, Gulec B, Akin ML. Persistent high postoperative carcinoembryonic antigen in colorectal cancer patients--is it important? Clinics (Sao Paulo). 2009;64(4):287-94.; Jeong S, Nam TK, Jeong JU, Kim SH, Kim K, Jang HS, et al. Postoperative carcinoembryonic antigen level has a prognostic value for distant metastasis and survival in rectal cancer patients who receive preoperative chemoradiotherapy and curative surgery: a retrospective multi-institutional analysis. Clin Exp Metastasis. 2016 Dec;33(8):809-816. DOI:10.1007/s10585-016-9818-6; Konishi T, Shimada Y, Hsu M, Tufts L, Jimenez-Rodriguez R, Cercek A, et al. Association of preoperative and postoperative serum carcinoembryonic antigen and colon cancer outcome. JAMA Oncol. 2018 Mar 1;4(3):309-315. DOI:10.1001/jamaoncol.2017.4420.; Meyerhardt JA, Mangu PB, Flynn PJ, Korde L, Loprinzi CL, Minsky BD, et al. Follow-up care, surveillance protocol, and secondary prevention measures for survivors of colorectal cancer: American Society of Clinical Oncology clinical practice guideline endorsement. J Clin Oncol. 2013 Dec 10;31(35):4465-70. DOI:10.1200/JCO.2013.50.7442.; Verberne CJ, Zhan Z, van den Heuvel E, Grossmann I, Doornbos PM, Havenga K, et al. Intensified follow-up in colorectal cancer patients using frequent Carcino-Embryonic Antigen (CEA) measurements and CEA-triggered imaging: Results of the randomized “CEAwatch” trial. Eur J Surg Oncol. 2015 Sep;41(9):118896. DOI:10.1016/j.ejso.2015.06.008.; Shinkins B, Primrose JN, Pugh SA, Nicholson BD, Perera R, James T, Mant D. Serum carcinoembryonic antigen trends for diagnosing colorectal cancer recurrence in the FACS randomized clinical trial. Br J Surg. 2018 May;105(6):658-662. DOI:10.1002/bjs.10819.; Perez RO, São Julião GP, Habr-Gama A, Kiss D, Proscurshim I, Campos FG, et al. The role of carcinoembriogenic antigen in predicting response and survival to neoadjuvant chemoradiotherapy for distal rectal cancer. Dis Colon Rectum. 2009 Jun;52(6):1137-43. doi:10.1007/DCR.0b013e31819ef76b.; Jang NY, Kang SB, Kim DW, Kim JH, Lee KW, Kim IA, Kim JS. The role of carcinoembryonic anti en after neoadjuvant chemoradiotherapy in pati ts with rectal cancer. Dis Colon Rectum. 2011 Feb;54(2):245-52. DOI:10.1007/DCR.0b013e3181fcee68.; Kim CW, Yu CS, Yang SS, Kim KH, Yoon YS, Yoon SN, et al. Clinical significance of pre-to post-chemoradiotherapy s-CEA reduction ratio in rectal cancer patients treated with preoperative chemoradiotherapy and curative resection. Ann Surg Oncol. 2011 Nov;18(12):3271-7. DOI:10.1245/s10434-011-1740-1; Sung SY, Son SH, Kay CS, Lee YS. Prognosis can be predicted more accurately using pre-and postchemoradiotherapy carcinoembryonic antigen levels compared to only prechemoradiotherapy carcinoembryonic antigen level in locally advanced rectal cancer patients who received neoadjuvant chemoradiotherapy. Medicine (Baltimore). 2016 Mar;95(10):e2965. DOI:10.1097/MD.0000000000002965.; Ryan JE, Warrier SK, Lynch AC, Heriot AG. Assessing pathological complete response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer: a systematic review. Colorectal Dis. 2015 Oct;17(10):849-61. DOI:10.1111/codi.13081; Каприн А.Д., Галкин В.Н., Жаворонков Л.П., Иванов В.К., Иванов С.А., Романко Ю.С. Синтез фундаментальных и прикладных исследований – основа обеспечения высокого уровня научных результатов и внедрения их в медицинскую практику. Радиация и риск. 2017;26(2):26-40. DOI:10.21870/0131-3878-2017-26-2-26-40; Wallin U, Rothenberger D, Lowry A, Luepker R, Mellgren A. CEA—a predictor for pathologic complete response after neoadjuvant therapy for rectal cancer. Dis Colon Rectum. 2013 Jul;56(7):859-68. DOI:10.1097/DCR.0b013e31828e5a72.; Park YA, Lee KY, Kim NK, Baik SH, Sohn SK, Cho CW. Prognostic effect of perioperative change of serum carcinoembryonic antigen level: a useful tool for detection of systemic recurrence in rectal cancer. Ann Surg Oncol. 2006 May;13(5):645-50. DOI:10.1245/ASO.2006.03.090; https://www.rpmj.ru/rpmj/article/view/265
-
8Academic Journal
Authors: A. Autenshlus I., T. Kunts A., K. Karpukhina V., E. Mikhailova S., N. Varaksin A., I. Marinkin O., А. Аутеншлюс И., Т. Кунц А., К. Карпухина В., Е. Михайлова С., Н. Вараксин А., И. Маринкин О.
Source: Bulletin of Siberian Medicine; Том 17, № 3 (2018); 5-12 ; Бюллетень сибирской медицины; Том 17, № 3 (2018); 5-12 ; 1819-3684 ; 1682-0363 ; 10.20538/1682-0363-2018-17-3
Subject Terms: canceroembryonic antigen, cytokines, invasive ductal carcinoma, fibroadenoma, pre-cancer, breast, раково-эмбриональный антиген, цитокины, инвазивный протоковый рак, фиброаденома, предраковые состояния, молочная железа
File Description: application/pdf
Relation: https://bulletin.tomsk.ru/jour/article/view/1278/818; Pavlopoulou A., Scorilas A. A comprehensive phylogenetic and structural analysis of the carcinoembryonic antigen (CEA) gene family. Genome Biol. Evol. 2014; 6 (6): 1314–1326. DOI:10.1093/gbe/evu103.; Duffy M.J. Carcinoembryonic antigen as a marker for colorectal cancer: is it clinically useful? Clinical Chemistry. 2001; 47 (4): 624–630. http://clinchem.aaccjnls.org/content/47/4/624.full; Гатауллин И.Г., Петров С.В., Валиев А.А., Шакиров Р.К. Прогностическая модель эффективности лечения больных колоректальным раком. Поволжский онкологический вестник. 2010; 1 (1): 27–30. http://elibrary.ru/item.asp?id=23498987.; Deng K., Yang L., Hu B., Wu H., Zhu H., Tang C. The prognostic significance of pretreatment serum CEA levels in gastric cancer: a meta-analysis including 14651 patients. Plos. One. 2015; 10: e124151. DOI:10.1371/journal.pone.0124151.; Kim C.H., M.D., Lee S.Y., Kim H.R., Kim Y.J. Prognostic effect of pretreatment serum carcinoembryonicantigen level: a useful tool for prediction of distant metastasis in locally advanced rectal cancer following neoadjuvant chemoradiotherapy and total mesorectal excision. Medicine. 2015; 94 (31): 1–7. DOI:10.1097/MD.0000000000001291.; Wang J., Wang X., Yu F., Chen J., Zhao S., Zhang D., Yu Y., Liu X., Tang H., Peng Z. Combined detection of preoperative serum CEA, CA19-9 and CA242 improve prognostic prediction of surgically. Int. J. Clin. Exp. Pathol. 2015; 8 (11): 14853–14863. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4713601; Grunnet M., Sorensen J.B. Carcinoembryonic antigen (CEA) as tumor marker in lung cancer. Lung Cancer. 2012; 76 (2): 138–143. DOI:10.1016/j.lungcan.2011.11.012.; Wang J.Y., Lu C.Y., Chu K.S., Ma C.J., Wu D.C., Tsai H.L., Yu F.J., Hsieh J.S. Prognostic significance of pre- and postoperative serum carcinoembryonic antigen levels in patients with colorectal cancer. Eur. Surg. Res. 2007; 39: 245–250. DOI:10.1159/000101952.; Bhatt A.N., Mathur R., Farooque A., Verma A., Dwarakanath B.S. Cancer biomarkers−current perspectives. Indian J. Med. Res. 2010; 132: 129–149. http://www.ijmr.org.in/downloadpdf.asp?issn=0971-5916;year=2010;volume=132;issue=2;spage=129;epage=149;aulast=Bhatt;type=2.; Lee J.S., Park S., Park J.M., Cho J.H., Kim S.I., Park B.W. Elevated levels of preoperative CA 15–3 and CEA serum levels have independently poor prognostic significance in breast cancer. Ann. Oncol. 2013; 24: 1225–1231. DOI:10.1093/annonc/mds604 PMID: 232301379.; Pedersen A.C., Sorensen P.D., Jacobsen E.H., Madsen J.S., Brandslund I. Sensitivity of CA 15–3, CEA and serum HER2 in the early detection of recurrence of breast cancer. Clin. Chem. Lab. Med. 2013; 51 (7): 1511–1519. DOI:10.1515/cclm-2012-0488 PMID: 23403727.; Wu S.G., He Z.Y., Zhou J., Sun J.Y., Li F.Y., Lin Q., Guo L., Lin H.X. Serum levels of CEA and CA15-3 in different molecular subtypes and prognostic value in Chinese breast cancer. Breast. 2014; 23: 88–93. DOI:10.1016/j.breast.2013.11.003 PMID: 24291374.; Wu L., Huang P., Wang F., Li D., Xie E., Zhang Y., Pan S. Relationship between serum CA19-9 and CEA levels and prognosis of pancreatic cancer. Ann. Transl. Med. 2015; 3 (21): 328–331. DOI:10.3978/j.issn.2305-5839.2015.11.17.; Hashiguchi Y., Kasai M., Fukuda T., Ichimura T., Yasui T., Sumi T. Serum carcinoembryonic antigen asa tumour marker in patients with endometrial cancer. Curr. Oncol. 2016; 23 (5): e439–e442. DOI:10.3747/co.23.3153.; Barak V., Meirovitz A., Leibovici V., Rachmut J., Peretz T., Eliashar R., Gross M. The diagnostic and prognosticn value of tumor markers (CEA, SCC, CYFRA 21-1, TPS) in head and neck cancer patients. Anticancer Res. 2015; 35 (10): 5519–5524. http://ar.iiarjournals.org/content/35/10/5519.long.; Saito H., Noji T., Okamura K., Tsuchikawa T., Shichinohe T., Hirano S. A new prognostic scoring system using factors available preoperatively to predict survival after operative resection of perihilar cholangiocarcinoma. Surgery. 2016; 159 (3): 842–851. DOI:10.1016/j.surg.2015.10.027.; Liska V., Treska V., Skalicky T., Fichtl J., Bruha J., Vycital O., Topolcan O. , Palek R., Rosendorf J., Polivka J., Holubec L. Evaluation of tumor markers and their impact on prognosis in gallbladder, bile duct and cholangiocellular carcinomas - a pilot study. Anticancer Res. 2017; 37 (4): 2003–2009. DOI:10.21873/anticanres.11544.; Tomita M., Ayabe T., Chosa E., Nose N., Nakamura K. Prognostic significance of a tumor marker index based on preoperative serum carcinoembryonic antigen and Krebs von den Lungen-6 levels in non-small cell lung cancer. Asian Pac. J. Cancer Prev. 2017; 18 (1): 287–291. DOI:10.22034/APJCP.2017.18.1.287.; Kim C.G., Ahn J.B., Jung M., Beom S.H., Heo S.J, Kim J.H., Kim Y.J., Kim N.K., Min B.S., Koom W.S., Kim H., Roh Y.H., Ma B.G., Shin S.J. Preoperative serum carcinoembryonic antigen level as a prognostic factor for recurrence and survival after curative resection followed by adjuvant chemotherapy in stage III colon cancer. Ann. Surg. Oncol. 2017; 24 (1): 227–235. DOI:10.1245/s10434-016-5613-5.; Gangopadhyay A., Lazure D., Thomas P. Adhesion of colorectal carcinoma cells to the endothelium is mediated by cytokines from CEA stimulated Kupffer cells. Clin. Exp. Metastasis. 1998; 16 (8): 703–712. https://www.ncbi.nlm.nih.gov/pubmed/10211983.; Семиглазов В.Ф., Айламазян Э.К., Байлюк Е.Н., Ниаури Д.А., Иванов В.Г, Манихас А.Г., Кветной И.М., Сошнев А.А. Профилактика рака молочной железы у больных пролиферативными процессами репродуктивной системы. Вопросы онкологии. 2006; 52 (3): 247–257. http://elibrary.ru/item.asp?id=13003090.; Патологическая анатомия: национальное руководство; под ред. М.А. Пальцева и др. М.: ГЭОТАР-Медиа, 2014: 1264.; Кунц Т.А., Карпухина К.В., Михайлова Е.С., Варак-син Н.А., Морозов Д.В., Аутеншлюс А.И. Цитокинпродуцирующий потенциал клеток крови при инвазивном протоковом раке и фиброаденоматозе молочной железы. Цитокины и воспаление. 2015; 14 (3): 47–52. http://elibrary.ru/item.asp?id=26511107.; Кунц Т.А., Карпухина К.В., Михайлова Е.С., Вараксин Н.А., Аутеншлюс А.И. Цитокиновый профиль супернатантов иммунокомпетентных клеток периферической крови и опухоли при инвазивном протоковом раке молочной железы. Современные проблемы науки и образования. 2016; 5: 103. https://science-education.ru/ru/article/view?id=25296.; Visscher D.W., Nassar A., Degnim A.C., Frost M.H., Vierkant R.A., Frank R.D., Tarabishy Y., Radisky D.C., Hartmann L.C. Sclerosing adenosis and risk of breast cancer. Breast Cancer Res. Treat. 2014; 144 (1): 205–212. DOI:10.1007/s10549-014-2862-5.; Cichon M.A., Degnim A.C., Visscher D.W., Radisky D.C. Microenvironmental influences that drive progression from benign breast disease to invasive breast cancer. J. Mammary Gland Biol. Neoplasia. 2010; 15 (4): 389–397. DOI:10.1007/s10911-010-9195-8.; https://bulletin.tomsk.ru/jour/article/view/1278
-
9Academic Journal
Authors: БИЛАН Р.С., БРАЖНИК К.И., ШАМС П.П., БАТИ Д., НАБИЕВ И.Р., СУХАНОВА АЛЕНА ВЛАДИМИРОВНА
Subject Terms: КВАНТОВЫЕ ТОЧКИ, ОДНОДОМЕННЫЕ АНТИТЕЛА, РАКОВО-ЭМБРИОНАЛЬНЫЙ АНТИГЕН, ДИАГНОСТИЧЕСКИЕ МЕТКИ
File Description: text/html
-
10Academic Journal
Authors: Газизова, Д., Бельцевич, Д.
Subject Terms: МЕДУЛЛЯРНЫЙ РАК ЩИТОВИДНОЙ ЖЕЛЕЗЫ, СИНДРОМ МНОЖЕСТВЕННЫХ ЭНДОКРИННЫХ НЕОПЛАЗИЙ 2 ТИПА, КАЛЬЦИТОНИН, РАКОВО-ЭМБРИОНАЛЬНЫЙ АНТИГЕН, RETПРОТООНКОГЕН
File Description: text/html
-
11Academic Journal
Authors: Матвеева, Любовь
Subject Terms: ОНКОМАРКЕР, РАК ЖЕЛУДКА, РАКОВО-ЭМБРИОНАЛЬНЫЙ АНТИГЕН, ТРОФОБЛАСТИЧЕСКИЙ B1-ГЛИКОПРОТЕИН, ФАКТОР РОСТА ЭНДОТЕЛИЯ СОСУДОВ, TROPHOBLASTIC β1-GLYCOPROTEIN
File Description: text/html
-
12Academic Journal
Authors: Оводов, Ю.
File Description: text/html
-
13Book
Authors: Линдін, Микола Сергійович, Лындин, Николай Сергеевич, Lyndin, Mykola Serhiiovych, Романюк, Анатолій Миколайович, Романюк, Анатолий Николаевич, Romaniuk, Anatolii Mykolaiovych, Сікора, Владислав Володимирович, Сикора, Владислав Владимирович, Sikora, Vladyslav Volodymyrovych, Зінгер, Б.Б.
Subject Terms: клітинна адгезія, клеточная адгезия, cell adhesion, раково-ембріональний антиген, раково-эмбриональный антиген, cancer-embryonic antigen, неопластична трансформація, неопластическая трансформация, neoplastic transformation
File Description: application/pdf
Availability: https://essuir.sumdu.edu.ua/handle/123456789/78862
-
14Academic Journal
Source: Проблемы здоровья и экологии.
Subject Terms: НИТРИТ-ИОНЫ, НИТРАТ-ИОНЫ, МОНООКСИД АЗОТА, ПРОСТАТ-СПЕЦИФИЧЕСКИЙ АНТИГЕН, РАКОВЫЙ АНТИГЕН 19-9, РАКОВО-ЭМБРИОНАЛЬНЫЙ АНТИГЕН, АЛЬФА-ФЕТОПРОТЕИН, PROSTATE SPECIFIC ANTIGEN (PSA), СARCINOEMBRYONIC ANTIGEN, 3. Good health
File Description: text/html
-
15Academic Journal
Source: Российский биотерапевтический журнал.
Subject Terms: 0301 basic medicine, 03 medical and health sciences, 0302 clinical medicine, КВАНТОВЫЕ ТОЧКИ, ОДНОДОМЕННЫЕ АНТИТЕЛА, РАКОВО-ЭМБРИОНАЛЬНЫЙ АНТИГЕН, ДИАГНОСТИЧЕСКИЕ МЕТКИ, 3. Good health
File Description: text/html
-
16Academic Journal
Source: Эндокринная хирургия.
Subject Terms: МЕДУЛЛЯРНЫЙ РАК ЩИТОВИДНОЙ ЖЕЛЕЗЫ, СИНДРОМ МНОЖЕСТВЕННЫХ ЭНДОКРИННЫХ НЕОПЛАЗИЙ 2 ТИПА, КАЛЬЦИТОНИН, РАКОВО-ЭМБРИОНАЛЬНЫЙ АНТИГЕН, RETПРОТООНКОГЕН, 3. Good health
File Description: text/html
-
17Academic Journal
Source: Медицинский альманах.
Subject Terms: 03 medical and health sciences, 0302 clinical medicine, ОНКОМАРКЕР, РАК ЖЕЛУДКА, РАКОВО-ЭМБРИОНАЛЬНЫЙ АНТИГЕН, ТРОФОБЛАСТИЧЕСКИЙ B1-ГЛИКОПРОТЕИН, ФАКТОР РОСТА ЭНДОТЕЛИЯ СОСУДОВ, TROPHOBLASTIC β1-GLYCOPROTEIN, 3. Good health
File Description: text/html
-
18Academic Journal
Source: Acta Naturae (русскоязычная версия).
File Description: text/html
-
19Academic Journal
Source: Медицинский вестник Башкортостана.
Subject Terms: РАК ЖЕЛУДКА, ОПУХОЛЕВЫЕ ОНКОМАРКЕРЫ СА 242 И РАКОВО-ЭМБРИОНАЛЬНЫЙ АНТИГЕН (РЭА), ЛЕЧЕНИЕ, ПРОГНОСТИЧЕСКОЕ ЗНАЧЕНИЕ, 3. Good health
File Description: text/html
-
20Academic Journal
Authors: Стародубцева, М. Н., Воропаев, Е. В., Петренёв, Д. Р., Беляковский, В. Н., Липская, Е. А., Конюшенко, Т. Ф.
Subject Terms: нитрит-ионы, нитрат-ионы, монооксид азота, простат-специфический антиген, раковый антиген 19-9, раково-эмбриональный антиген, альфа-фетопротеин
Relation: Распределение концентрации нитрит- и нитрат-ионов в крови жителей Гомельской области в зависимости от концентрации онкомаркеров (простат-специфического антигена, ракового антигена 19-9, раково-эмбрионального антигена и альфа-фетопротеина) / М. Н. Стародубцева, Е. В. Воропаев, Д. Р. Петренёв, В. Н. Беляковский, Е. А. Липская, Т. Ф. Конюшенко // Проблемы здоровья и экологии. - 2014. - №4 (42). - С.101-106.; https://elib.gsmu.by/handle/GomSMU/457
Availability: https://elib.gsmu.by/handle/GomSMU/457
